Leptin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Leptin (obesity homolog, mouse)
| ||||||||||||||
| ||||||||||||||
| PDB rendering based on 1ax8. | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | LEP; OB; OBS | |||||||||||||
| External IDs | OMIM: 164160 MGI: 104663 Homologene: 193 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
|
| ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 3952 | 16846 | ||||||||||||
| Ensembl | ENSG00000174697 | ENSMUSG00000059201 | ||||||||||||
| Uniprot | P41159 | Q544U0 | ||||||||||||
| Refseq | NM_000230 (mRNA) NP_000221 (protein) | NM_008493 (mRNA) NP_032519 (protein) | ||||||||||||
| Location | Chr 7: 127.67 - 127.68 Mb | Chr 6: 29.01 - 29.02 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
| Identifiers | |
| Symbol | LEPR |
| Entrez | 3953 |
| HUGO | 6554 |
| OMIM | 601007 |
| RefSeq | NM_002303 |
| UniProt | P48357 |
| Other data | |
| Locus | Chr. 1 p31 |
|
WikiDoc Resources for Leptin | |
|
Articles | |
|---|---|
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Leptin at Clinical Trials.gov Clinical Trials on Leptin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Leptin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Directions to Hospitals Treating Leptin Risk calculators and risk factors for Leptin
| |
|
Healthcare Provider Resources | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Leptin (from the Greek word leptos, meaning thin) is a 16 kDa protein hormone that plays a key role in regulating energy intake and energy expenditure, including the regulation (decrease) of appetite and (increase) of metabolism.
The effects of leptin were observed by studying mutant obese mice that arose at random within a mouse colony at the Jackson Laboratory in 1950. These mice were massively obese and hyperphagic. Leptin itself was discovered in 1994 by Jeffrey M. Friedman and colleagues at the Rockefeller University through the study of those mutant mice. The Ob(Lep) gene (Ob for obese and Lep for leptin) is located on chromosome 7 in humans. Leptin is produced by adipose tissue and interacts with six types of receptor (LepRa–LepRf). LepRb is the only receptor isoform that contains active intracellular signaling domains. This receptor is present in a number of hypothalamic nuclei, where it exerts its effects. Importantly, leptin binds to the ventral medial nucleus of the hypothalamus, known as the "appetite center." Binding of leptin to this nucleus signals to the brain that the body has had enough to eat—a sensation of satiety. A very small group of humans possess homozygous mutations for the leptin gene which lead to a constant demand for food, resulting in severe obesity. This condition can be successfully treated by the administration of recombinant human leptin.[1]
Thus, circulating leptin levels give the brain a reading of energy storage for the purposes of regulating appetite and metabolism. Leptin works by inhibiting the activity of neurons that contain neuropeptide Y (NPY) and agouti-related peptide (AgRP), and by increasing the activity of neurons expressing α-melanocyte-stimulating hormone (α-MSH). The NPY neurons are a key element in the regulation of appetite; small doses of NPY injected into the brains of experimental animals stimulates feeding, while selective destruction of the NPY neurons in mice causes them to become anorexic. Conversely, α-MSH is an important mediator of satiety, and differences in the gene for the receptor at which α-MSH acts in the brain are linked to obesity in humans.
Leptin is also regulated (downward) by melatonin during the night.[1] Brazilian researchers found in 2004 that, in the presence of insulin, "melatonin interacts with insulin and upregulates insulin-stimulated leptin expression."[1]
Leptin as adiposity signal
To date, only leptin and insulin fulfill the criteria of an adiposity signal:
- It circulates at levels proportional to body fat.
- It enters the central nervous system (CNS) in proportion to its plasma concentration.
- Its receptors are found in brain neurons involved in regulating energy intake and expenditure.
Mechanism of action
It is unknown whether leptin can cross the blood-brain barrier to access receptor neurons, because the blood-brain barrier is somewhat absent in the area of the median eminence, close to where the NPY neurons of the arcuate nucleus are. If it does cross the blood-brain barrier, it is unknown whether this occurs via an active or passive process. It is generally thought that leptin might enter the brain at the choroid plexus, where there is intense expression of a form of leptin receptor molecule that might act as a transport mechanism.
Once leptin has bound to the Ob-Rb receptor, it activates the molecule stat3, which is phosphorylated and travels to the nucleus, it is presumed, to effect changes in gene expression. One of the main effects on gene expression is the down-regulation of the expression of endocannabinoids, responsible—among their many other functions—for increasing appetite. There are other intracellular pathways activated by leptin, but less is known about how they function in this system. In response to leptin, receptor neurons have been shown to remodel themselves, changing the number and types of synapses that fire onto them.
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin.[1] These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite signals from circulating leptin. The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.
In mice, leptin is also required for male and female fertility. In mammals generally, and in humans in particular, puberty in females is linked to a critical level of body fat. When fat levels fall below this threshold (as in anorexia), the ovarian cycle stops and females stop menstruating.
Leptin is also strongly linked with angiogenesis, increasing VEGF levels.
Leptin and reproduction
The body's fat cells, under normal conditions, are responsible for the constant production and release of leptin. This can also be produced by the placenta.[1] Leptin levels rise during pregnancy and fall at parturition (childbirth). Leptin is also expressed in fetal membranes and uterine tissue. Uterine muscle contractions are inhibited by leptin.[1]
Recent discoveries
Professor Cappuccio of the University of Warwick has recently discovered that short sleep duration may lead to obesity, through an increase of appetite via hormonal changes. Lack of sleep produces ghrelin which, among other effects, stimulates appetite and creates less leptin which, amongst its many other effects, suppresses appetite.
Next to a biomarker for body fat, serum leptin levels also reflect individual energy balance. Several studies have shown that fasting or following a very low calorie diet (VLCD) lowers leptin levels.[1] It might be that on short term leptin is an indicator of energy balance. In line with evolution this system is more sensitive to starvation than to overfeeding,[1] i.e. leptin levels do not rise extensively after overfeeding. It might be that the dynamics of leptin due to an acute change in energy balance are related to appetite and eventually in food intake. Although this is a new hypothesis, there is already some data that supports it.[1][1]
There is gradual recognition that leptin action is more decentralized than previously assumed. In addition to its endocrine action at a distance (from adipose tissue to brain), leptin also acts as a paracrine mediator.[1] In fetal lung leptin is induced in the alveolar interstitial fibroblasts ("lipofibroblasts") by the action of PTHrP secreted by formative alveolar epithelium (endoderm) under moderate stretch. The leptin from the mesenchyme in turn acts back on the epithelium at the leptin receptor carried in the alveolar type II pneumocytes and induces surfactant expression which is one of the main functions of these type II pneumocytes.[1] In addition to white adipose tissue -the major source of leptin, it can also be produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, stomach (lower part of fundic glands), mammary epithelial cells, bone marrow, pituitary and liver.[1]
There is also evidence that leptin plays a role in hyperemesis gravidarum (severe morning sickness),[1] in polycystic ovary syndrome[1] and a 2007 research suggest that hypothalamic leptin is implicated in bone growth.[1]
Modulation of T cells activity in immune system
The important role of Leptin/Leptin receptors were shown in this experiment with mice. It modulates the immune response to atherosclerosis, which is a predisposing factor in patients with obesity. [1]
References
Further reading
- Torday JS, Sun H, Wang L, Torres E, Sunday ME, Rubin LP (Mar 2002). "Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation". Am. J. Physiol. Lung Cell Mol. Physiol. 282 (3): L405-10. PMID 11839533.
- Torday JS, Rehan VK (Jul 2002). "Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin". Am. J. Physiol. Lung Cell Mol. Physiol. 283 (1): L130-5. PMID 12060569.
- Friedman JM, Halaas JL (1998). "Leptin and the regulation of body weight in mammals.". Nature 395 (6704): 763-70. doi:10.1038/27376. PMID 9796811.
- Prolo P, Wong ML, Licinio J (1999). "Leptin.". Int. J. Biochem. Cell Biol. 30 (12): 1285-90. PMID 9924798.
- Heshka JT, Jones PJ (2001). "A role for dietary fat in leptin receptor, OB-Rb, function.". Life Sci. 69 (9): 987-1003. PMID 11508653.
- Janeckova R (2002). "The role of leptin in human physiology and pathophysiology.". Physiological research / Academia Scientiarum Bohemoslovaca 50 (5): 443-59. PMID 11702849.
- Lee DW, Leinung MC, Rozhavskaya-Arena M, Grasso P (2002). "Leptin and the treatment of obesity: its current status.". Eur. J. Pharmacol. 440 (2-3): 129-39. PMID 12007531.
- Al-Daghri N, Bartlett WA, Jones AF, Kumar S (2002). "Role of leptin in glucose metabolism in type 2 diabetes.". Diabetes, obesity & metabolism 4 (3): 147-55. PMID 12047393.
- Sabath Silva EF (2002). "[Leptin]". Rev. Invest. Clin. 54 (2): 161-5. PMID 12053815.
- Thomas T, Burguera B (2003). "Is leptin the link between fat and bone mass?". J. Bone Miner. Res. 17 (9): 1563-9. PMID 12211425.
- Kraemer RR, Chu H, Castracane VD (2002). "Leptin and exercise.". Exp. Biol. Med. (Maywood) 227 (9): 701-8. PMID 12324651.
- Waelput W, Brouckaert P, Broekaert D, Tavernier J (2003). "A role for leptin in the systemic inflammatory response syndrome (SIRS) and in immune response.". Current drug targets. Inflammation and allergy 1 (3): 277-89. PMID 14561193.
- Stenvinkel P, Pecoits-Filho R, Lindholm B (2004). "Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?". Advances in renal replacement therapy 10 (4): 332-45. PMID 14681862.
- Cohen P, Ntambi JM, Friedman JM (2004). "Stearoyl-CoA desaturase-1 and the metabolic syndrome.". Curr. Drug Targets Immune Endocr. Metabol. Disord. 3 (4): 271-80. PMID 14683458.
- Sahu A (2004). "Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance.". Frontiers in neuroendocrinology 24 (4): 225-53. PMID 14726256.
- Elefteriou F, Karsenty G (2004). "[Bone mass regulation by leptin: a hypothalamic control of bone formation]". Pathol. Biol. 52 (3): 148-53. doi:10.1016/j.patbio.2003.05.006. PMID 15063934.
- Blüher S, Mantzoros CS (2004). "The role of leptin in regulating neuroendocrine function in humans.". J. Nutr. 134 (9): 2469S-2474S. PMID 15333744.
- Farooqi S, O'Rahilly S (2007). "Genetics of obesity in humans.". Endocr. Rev. 27 (7): 710-18. doi:10.1210/er.2006-0040. PMID 17122358.
External links
- http://www.scq.ubc.ca/?p=421 Leptin biology from the Science Creative Quarterly], well written and illustrated
- Leptin in a bulletin by the Howard Hughes Medical Institute (HHMI)
- Review article "Leptin and the regulation of body weight in mammals" from Nature, requires subscription
- Leptin: Your brain, appetite and obesity by the British Society of Neuroendocrinology
- Leptin/ghrelin and their role in obesity from hungerhormones.com, a weight control website
- Leptin by Colorado State University
- Leptin at 3Dchem.com, description and structure diagrams
ca:Leptina de:Leptinfr:Leptine it:Leptina he:לפטין nl:Leptine ja:レプチンsv:Leptin
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
